alexa Targeting Dys-Regulated Reactive Oxygen Species Homeostasis in Cancer
ISSN: 2376-1318
Vitamins & Minerals
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Targeting Dys-Regulated Reactive Oxygen Species Homeostasis in Cancer as a Selective Chemotherapeutic Approach

Danuta S. Kalinowski1* and Des R. Richardson1
1Iron Metabolism and Chelation Program, Department of Pathology, Bosch Institute, University of Sydney, Sydney, Australia
Corresponding Author : Dr. Danuta S. Kalinowski
Department of Pathology, Bosch Institute
University of Sydney, Sydney
New South Wales, 2006 Australia
Tel: +61-2- 90366547
Fax: +61-2-93513429
Received April 12, 2012; Accepted April 12, 2012; Published April 16, 2012
Citation: Kalinowski DS, Richardson DR (2012) Targeting Dys-Regulated Reactive Oxygen Species Homeostasis in Cancer as a Selective Chemotherapeutic Approach. Vitam Trace Elem 1:e113. doi:10.4172/2167-0390.1000e113
Copyright: © 2012 Kalinowski DS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Vitamins & Minerals

The development of resistance by cancer cells to established chemotherapeutics is a key issue in the clinical treatment of this devastating disease and has necessitated the generation of therapeutic agents that utilize novel targeting strategies [1]. Identifying crucial biochemical alterations between cancer cells and their normal counterparts is critical in the design of potent chemotherapeutics that maintain selectivity and overcome drug resistance [2]. Importantly, the increase in oxidative stress and reactive oxygen species (ROS) generation observed in cancer cells, in comparison to their normal counterparts, has been highlighted as a possible selective targeting strategy [2]. Thus, the use of agents that are able to modulate levels of intracellular ROS in oxidatively stressed cancer cells forms a potential chemotherapeutic approach.
In normal cells, the maintenance of ROS homeostasis is essential for survival and growth [2]. In fact, ROS are essential in biological signaling transduction pathways and the regulation of enzyme activity, such as ribonucleotide reductase (RR) [3]. Importantly, RR is an ironcontaining enzyme involved in the rate-limiting step of DNA synthesis that has previously acted as a chemotherapeutic target for hydroxyurea [1]. While moderate levels of ROS promote cellular proliferation and differentiation, excessive ROS levels are toxic and can result in oxidative damage to vital biomolecules, including DNA, proteins and lipids [1]. Thus, ROS homeostasis is achieved by balancing ROS production and elimination that occurs through endogenous scavenging systems such as catalase, thioredoxin and superoxide dismutase [2,3].
In vitro and in vivo studies and clinical specimens have demonstrated that neoplastic cells function with increased levels of oxidative stress compared to normal cells [4-7]. This is evident in the increased levels of oxidation products, such as lipid peroxides and oxidized DNA bases in cancer cells [7,8] and is thought to result from factors including mitochondrial dysregulation and activation of oncogenes [9-11]. Furthermore, levels of ROS-scavenging molecules and enzyme systems have been previously assessed in primary and malignant tumors (e.g. colorectal, lung and ovarian cancer) and compared to normal noncancerous tissue [12-16]. Interestingly, the majority of cancer types show an imbalance in anti-oxidant enzyme levels in comparison to the cell of origin [14]. For example, decreased levels of radical-scavenging systems (e.g. reduced glutathione, glutathione peroxidase 1 and 3, and glutathione reductase) have been observed in a number of cancer types (e.g. colorectal cancer, glioblastoma multiforme and transitional meningioma), in comparison to normal tissue [13,14,16]. In contrast, ovarian cancers display increased levels of superoxide dismutase and this increase is believed to be a cellular response to increased ROS levels [12]. These factors indicate a dys-regulation in ROS homeostasis in tumors [12-15] and suggest that cancer cells are more susceptible than normal cells to insult by agents that further disrupt ROS homeostasis. Thus, exogenous agents that increase intracellular ROS levels, such as iron chelators that form redox active complexes [17,18], are an exciting chemotherapeutic avenue.
Interest in thiosemicarbazone iron chelators as anti-cancer agents has increased in recent years, with the ligand, Triapine®, entering >20 international clinical trials [19]. Additionally, a number of thiosemicarbazone analogues, including di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and 2-benzoylpyridine 4,4-dimethyl-3-thiosemicarbazone (Bp44mT), overcome resistance to established chemotherapeutics and have demonstrated potent and selective anti-cancer activity against a number of human tumor xenografts in vivo [20,21].
Importantly, the anti-proliferative activity of thiosemicarbazones is not only due to the chelation of the essential nutrient, iron, but also results from the formation of redox-active iron complexes [17,18]. Once formed, these iron complexes are able to participate in Fenton-like chemistry to generate ROS and can interact with cellular oxidants and reductants, establishing a catalytic redox cycling mechanism [1,17,18]. Significantly, Dp44mT and Bp44mT were shown to alter important thiol-related anti-oxidant systems in vitro, including glutathione, thioredoxin and glutaredoxin [3]. In fact, these iron chelators significantly increased the levels of oxidized trimeric thioredoxin and was most likely due to their ability to inhibit thioredoxin reductase activity [3]. Moreover, these ligands also resulted in the inhibition of glutathione reductase activity, which is responsible for the generation of reduced glutathione, an important cellular anti-oxidant [3]. Such thiol-containing systems provide reducing equivalents for RR, the enzyme involved in the rate-limiting step of DNA synthesis [3]. Thus, targeting these systems also reduce the activity of RR [3] and these studies provide further insight into the mechanisms involved in the anti-cancer activity of thiosemicarbazones [3].
Collectively, agents that can modulate levels of intracellular ROS, either through the increase in ROS generation and/or the inhibition of ROS-scavenging capacity, form a potential therapeutic avenue to selectively target cancer [2]. In this light, novel thiosemicarbazone iron chelators, such as Dp44mT and Bp44mT, have emerged as potent and selective anti-cancer agents that act via multiple mechanisms, including: (1) the chelation of iron from biological systems [1,17,18]; (2) the formation of redox active iron complexes [1,17,18]; and (3) the alteration of thiol-containing anti-oxidant systems to inhibit RR activity [3]. Significantly, the targeting of multiple cellular systems is an important strategy in design of selective agents that overcome resistance to established chemotherapeutics. The ability of these chelators to target cellular anti-oxidant systems, which are already compromised in many cancer types, may explain the potent and selective anti-cancer activity of these ligands observed in vivo [20,21].

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 3803
  • [From(publication date):
    May-2012 - Jul 21, 2017]
  • Breakdown by view type
  • HTML page views : 61
  • PDF downloads :3742

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version